RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance

Core Viewpoint - RxSight, Inc. has announced preliminary revenue results for Q1 2025 and revised its full-year guidance, indicating challenges in the premium IOL market and broader economic conditions affecting its operations [1][3][4]. Preliminary First Quarter 2025 Results - The preliminary revenue for Q1 2025 is expected to be approximately $37.9 million, reflecting a 28% increase compared to the same period last year, but a 6% decrease from Q4 2024 [8]. - The company sold 27,579 Light Adjustable Lenses (LAL™/LAL+®), marking a 36% increase in procedure volume year-over-year [8]. - The installed base of Light Delivery Devices (LDD™) has expanded to 1,044, a 43% increase from 732 LDDs at the end of Q1 2024 [8]. Revised 2025 Guidance - The company has lowered its full-year revenue guidance to a range of$ 160.0 million to $175.0 million, down from the previous range of$ 185.0 million to $197.0 million, indicating an implied growth of 14% to 25% compared to 2024 [9]. - Operating expenses are now projected to be between$ 150.0 million and $160.0 million, reduced from the previous guidance of$ 165.0 million to $170.0 million, representing an implied increase of 10% to 18% compared to 2024 [9]. - Non-cash stock-based compensation expense is now expected to be in the range of$ 27.0 million to $30.0 million, up from the previous range of$ 22.0 million to $25.0 million [9]. Company Overview - RxSight, Inc. specializes in ophthalmic medical devices, particularly focusing on providing customized vision solutions for patients post-cataract surgery [1][10]. - The RxSight® Light Adjustable Lens system is the first and only commercially available intraocular lens technology that can be adjusted after surgery, allowing for tailored vision correction [10].